SINOVAC’s COVID-19 vaccine approved for use in children over 6 months of age in Hong Kong

Beijing (China), August 03, 2022–(BUSINESS WIRE)–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a number one provider of biopharmaceuticals in China, introduced that, based mostly on related medical trials and vaccination research for native children and adolescents, the Department of Health of the Hong Kong Government of the People’s Republic of China’s Kong Special Administrative Region of the Company has approved a Covid-19 vaccine (titled Coronavac), supposed for children aged six months to 3 years.

The vaccination schedule for this age group follows the identical mannequin as for older children. Three doses of the vaccine can be used for children aged six months to underneath three years, with the primary two doses given 28 days aside, adopted by the third dose no less than three months after the second dose – and there’s no restriction on software. For immunosuppressed children.

The Scientific Committee on Vaccine-Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases of the Department of Health’s Center for Health Security, together with the Executive (*6*) Expert Advisory Panel, issued interim consensus suggestions on vaccine use. COVID-19 for children six months and older in Hong Kong on August 1, 2022.

In 2021, SINOVAC started Phase III medical trials of a Covid-19 vaccine (Coronavac) in children aged six months to 17 years. Preliminary outcomes present that the vaccine has a great security and immunogenicity profile, with no severe adversarial reactions reported as much as six months after two doses of vaccination in children aged six to 35 months.

CoronaVac was approved in Hong Kong on February 15, 2022 for emergency use on minors and adults over three years of age. As of August 2022, CoronaVac is approved for use on minors in 14 Latin American international locations, together with Chile, Colombia, Ecuador. , Brazil, in addition to different international locations in the Asia and Africa areas.

About SINOVAC

Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical firm centered on R&D, manufacturing and advertising of vaccines that defend towards human infectious ailments.

SINOVAC’s product portfolio contains vaccines towards Covid-19, enterovirus 71 (EV71) contaminated hand-foot-and-mouth illness, hepatitis A and B, seasonal influenza, pneumococcal illness, H5N1 pandemic influenza (avian flu), H1N1 influenza (avian flu). occurs , chickenpox, mumps and polio.

Your COVID-19 vaccine, known as CoronaVac®, has been approved for use in greater than 60 international locations and territories worldwide. The Hellev®Hepatitis A vaccine exceeded WHO prequalification necessities in 2017. EV71 vaccine, inlive®is a novel vaccine marketed in China in 2016. In 2022, SINOVAC’s Sabine strain-inactivated polio vaccine (sIPV) was pre-qualified by the WHO.

SINOVAC was the primary firm to obtain approval for its H1N1 flu vaccine, named Panflu.1.®, supplied in the Chinese authorities’s vaccination marketing campaign and assortment program. The firm can be the only real provider of the H5N1 pandemic influenza vaccine, Panflu.®For the Chinese authorities’s storage program.

SINOVAC is constantly engaged in analysis and growth of new vaccines with extra mixture merchandise in its pipeline and is continually exploring international market alternatives. The firm plans to have interaction in broader and deeper commerce and cooperation with different international locations and enterprise and industrial associations.

For extra info, go to the SINOVAC web site: www.sinovac.com.

The unique language textual content of this commercial is the official approved model. Translations are supplied solely as a comfort and will seek advice from the textual content in the unique language, which is the one model of the textual content that has authorized impact.

See the unique model at businesswire.com: https://www.businesswire.com/information/house/20220803005374/en/

contacts

Sinovac Biotech Ltd.
PR crew
pr@sinovac.com

ICR Inc.
Bill Zima
USA: 1-646-308-1707
william.zima@icrinc.com

Leave a Comment